Many pharmaceutical stocks closed up and down, and one stock recorded 4 days and 3 boards!

According to data from the Oriental Fortune Network Market Center, as of the close of December 8, many pharmaceutical stocks closed up and down, including Haichen Pharmaceutical, Qianhong Pharmaceutical, Xinhua Pharmaceutical, etc.
, of which Xinhua Pharmaceutical recorded 4 days and 3 boards, Haichen Pharmaceutical rose more than 13%, in addition, ursodeoxycholic acid concept stock Common Pharmaceutical rose 8.
42%, and Chinese medicine stocks Yiling Pharmaceutical, Shuangcheng Pharmaceutical, etc.
all rose more than 5%.

As of the close of trading on December 8, Haichen Pharmaceutical rose by 13.
33%, with a quotation of 36.
99 yuan, a volume of 229,700 and a turnover of 821 million
.
The sectors to which Haichen Pharmaceutical belongs include GEM + pox virus prevention and control + chemical pharmaceuticals + ursodeoxycholic acid + Helicobacter pylori concept, etc
.
The company and its subsidiaries are mainly engaged in the research and development, production and sales of chemical preparations, APIs and intermediates, and the main products cover diuretic, cardiovascular, anti-infective, digestive system, immunomodulation, hypoglycemia, orthopedics and other therapeutic fields
.
On December 8, 2022, Haichen Pharmaceutical issued an announcement that the approval of the company's montelukast sodium chewable tablets will enrich the company's respiratory product line and have a positive impact
on the company's future performance.
In addition, on October 21, the company announced that the approval of the company's dabigatran etexilate capsules is mainly used to prevent stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, and the approval of this product further enriches the company's cardiovascular product line, and this approval is regarded as passing the consistency evaluation
.
As of the close on December 8, Qianhong Pharmaceutical rose 10.
03%, with a quotation of 7.
35 yuan, a volume of 2.
5711 million, and a turnover of 1.
863 billion
.
Qianhong Pharmaceutical's sector involves virus prevention and control + heparin concept + hepatitis concept + chemical pharmaceutical, etc.
, the stock was connected yesterday, and the price limit contains one word
.
The company is the head enterprise of protease and polysaccharide drugs, and it is also one of the few pharmaceutical manufacturers covering the whole industry chain of heparin in China
.
The company's main products are heparin sodium (heparin sodium API, heparin preparation), pancreatic kallikrein (enteric-coated tablets, pancreatic kallikrein for injection), asparaginase for injection
.
On the news, Qianhong Pharmaceutical disclosed a stock trading change announcement on the evening of December 8, saying that the indications of the company's current product ursodeoxycholic acid tablets are cholesterol-type gallstones, formation and bile deficiency steatorrhea, prevention of drug-induced stone formation and treatment of steatorrhea
.
As of the close of trading on December 8, Xinhua Pharmaceutical rose 10.
01%, with a quotation of 29.
66 yuan, a volume of 873,300 and a turnover of 2.
567 billion
.
The stock has recorded 3 boards
in 4 days.
The analysis believes that the cause of the change is mainly related
to the concept of ursodeoxycholic acid + FTSE Russell + ibuprofen.
The company is mainly engaged in the development, manufacture and sales of chemical APIs, preparations, pharmaceutical intermediates and other products, and has formed seven API product series such as Wuan series, caffeine series, ibuprofen series, aspirin series, dopa series, barbiturate series, pyroperic acid, etc.
, with outstanding
scale advantages.
As the head company of ibuprofen, the company recently said on the investor interactive platform that the actual market share of the company ibuprofen is close to 40%.

Xinhua Pharmaceutical has not disclosed the production capacity of ibuprofen at present, but according to the 2021 prospectus of Hendi Pharmaceutical, the former's ibuprofen production capacity is 8,000 tons/year, and the customers are mainly
overseas ibuprofen preparation manufacturers.
In the construction project in the company's 2021 annual report, the estimated production capacity called "Ibuprofen expansion and synthesis process capacity improvement transformation" is shown as 10,000 tons per year, and the construction period is 1.
5 years
.
In addition, on December 8, Xinhua Pharmaceutical said on the investor interactive platform that the company's production and operation were normal
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.